Evaluation of miR-504-3p and miR-711 expression levels as diagnostic biomarkers in peripheral blood of responders and non responders to interferon-Beta in people with multiple sclerosis

Abstract

Multiple sclerosis is immune-mediated disease of the central nervous system characterized by demyelination in axons. IFN-β is first-line treatment of MS. Biomarkers are needed for early prediction of responders and non responders to therapy in the first month of treatment to avoid further disabilities. Methods: In this study, we analyzed the expression level of miR-504 and miR-711 in 52 IFN-β responder patients in comparison to 53 non-responders. In the next step, the in-silico analysis was used to enrich related signaling pathways Results: The expression level of miR-504 was significantly higher in patients who respond to IFN-β therapy, compared with non-responders and we obtain related statistically significant KEGG molecular signaling